Share on StockTwits
 

Medivation (NASDAQ:MDVN) CFO Clarence Patrick Machado sold 40,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $76.29, for a total value of $3,051,600.00. Following the completion of the sale, the chief financial officer now directly owns 30,830 shares in the company, valued at approximately $2,352,021. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

A number of research firms have recently commented on MDVN. Analysts at Zacks reiterated a “neutral” rating on shares of Medivation in a research note to investors on Monday, January 13th. They now have a $76.00 price target on the stock. Separately, analysts at Barclays raised their price target on shares of Medivation from $57.00 to $62.00 in a research note to investors on Friday, January 10th. They now have an “equal weight” rating on the stock. Finally, analysts at UBS AG reiterated a “positive” rating on shares of Medivation in a research note to investors on Wednesday, December 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the company’s stock. Medivation presently has a consensus rating of “Buy” and a consensus target price of $68.40.

Medivation (NASDAQ:MDVN) traded up 0.01% during mid-day trading on Thursday, hitting $78.69. The stock had a trading volume of 1,231,277 shares. Medivation has a 1-year low of $41.89 and a 1-year high of $79.46. The stock has a 50-day moving average of $67.00 and a 200-day moving average of $60.31. The company’s market cap is $5.938 billion.

Medivation (NASDAQ:MDVN) last released its earnings data on Tuesday, November 12th. The company reported ($0.18) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.26) by $0.08. The company had revenue of $108.50 million for the quarter, compared to the consensus estimate of $60.13 million. During the same quarter in the prior year, the company posted ($0.06) earnings per share. The company’s quarterly revenue was down 7.4% on a year-over-year basis. Analysts expect that Medivation will post $-0.70 EPS for the current fiscal year.

Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.